Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery
Open Access
- 10 October 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (10) , e0185926
Abstract
After advanced age, female sex is the major risk factor for Alzheimer’s disease (AD). The biological mechanisms underlying the increased AD risk in women remain largely undetermined. Preclinical studies identified the perimenopause to menopause transition, a neuroendocrine transition state unique to the female, as a sex-specific risk factor for AD. In animals, estrogenic regulation of cerebral glucose metabolism (CMRglc) falters during perimenopause. This is evident in glucose hypometabolism and decline in mitochondrial efficiency which is sustained thereafter. This study bridges basic to clinical science to characterize brain bioenergetics in a cohort of forty-three, 40–60 year-old clinically and cognitively normal women at different endocrine transition stages including premenopause (controls, CNT, n = 15), perimenopause (PERI, n = 14) and postmenopause (MENO, n = 14). All participants received clinical, laboratory and neuropsychological examinations, 18F-fluoro-deoxyglucose (FDG)-Positron Emission Tomography (PET) FDG-PET scans to estimate CMRglc, and platelet mitochondrial cytochrome oxidase (COX) activity measures. Statistical parametric mapping and multiple regression models were used to examine clinical, CMRglc and COX data across groups. As expected, the MENO group was older than PERI and controls. Groups were otherwise comparable for clinical measures and distribution of APOE4 genotype. Both MENO and PERI groups exhibited reduced CMRglc in AD-vulnerable regions which was correlated with decline in mitochondrial COX activity compared to CNT (p’s<0.001). A gradient in biomarker abnormalities was most pronounced in MENO, intermediate in PERI, and lowest in CNT (p<0.001). Biomarkers correlated with immediate and delayed memory scores (Pearson’s 0.26≤r≤0.32, p≤0.05). These findings validate earlier preclinical findings and indicate emergence of bioenergetic deficits in perimenopausal and postmenopausal women, suggesting that the optimal window of opportunity for therapeutic intervention in women is early in the endocrine aging process.Keywords
Funding Information
- National Institutes of Health (AG035137)
- National Institutes of Health (P01AG026572)
This publication has 62 references indexed in Scilit:
- Preclinical Alzheimer disease—the challenges aheadNature Reviews Neurology, 2012
- Insulin resistance and hippocampal volume in women at risk for Alzheimer's diseaseNeurobiology of Aging, 2011
- Perimenopause and CognitionObstetrics and Gynecology Clinics of North America, 2011
- The SWAN Song: Study of Women’s Health Across the Nation’s Recurring ThemesObstetrics and Gynecology Clinics of North America, 2011
- Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for ADPsychoneuroendocrinology, 2011
- Estrogen-induced plasticity from cells to circuits: predictions for cognitive functionTrends in Pharmacological Sciences, 2009
- FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline.Neuropsychology, 2008
- Hippocampal hypometabolism predicts cognitive decline from normal agingNeurobiology of Aging, 2008
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006